Mologic develops lateral flow and rapid diagnostic technologies, products and services for human healthcare, agriculture and aquaculture. Co-Founder and CSO Paul Davis developed the Clearblue pregnancy test launched in 1988, which was the world’s first commercial application of lateral flow technology. Mologic offers device and reagent products for clinical and commercial applications and scientific research expertise for contract R&D.
Mologic is collaborating with the Senegalese research foundation Institut Paseur de Dakar to develop a 10 minute COVID-19 diagnostic test. The test will use technology from home pregnancy tests and malaria tests and offer a saliva and finger-prick blood test. In Africa the tests are planned to be manufactured in Senegal by DiaTropix, a diagnostics manufacturing facility led by Amandou Alpha Sall, director of the Pasteur Institute. Mologic and the Institut Pasteur have joint capacity to produce 8 million tests per year with plans to sell directly to African governments, the Global Alliance for Vaccines and Immunizations and the WHO. Mologic seeks a manufacturing facility to produce tests in the UK. Mologic received £1 million ($1.2 million) funding from the U.K. government for the development of the COVID-19 diagnostic test.